Lineage Cell Therapeutics (LCTX) Operating Leases (2014 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Operating Leases of $1.5 million for Q1 2026, up 48.77% year-over-year from $1.0 million in Q1 2025, and down 1.76% quarter-over-quarter from $1.5 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Operating Leases (2014 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Operating Leases history runs 13 years deep, the most recent figure standing at $1.5 million for Q1 2026.
- In Q1 2026, Operating Leases rose 48.77% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (up 48.77% YoY), while the FY2025 annual figure was $1.5 million, up 18.46% from the prior year.
- Operating Leases for Q1 2026 stood at $1.5 million, down from $1.5 million in the prior quarter.
- The five-year high for Operating Leases was $2.9 million in Q4 2022, with the low at $1.0 million in Q1 2025.
- The 5-year median for Operating Leases is $1.8 million (2024), against an average of $1.8 million.
- The sharpest annual moves came in 2023 and 2025: Operating Leases surged 57.92% in 2023, then plunged 51.16% in 2025.
- Lineage Cell Therapeutics' Operating Leases stood at $2.9 million in 2022, then sank by 30.8% to $2.0 million in 2023, then sank by 34.56% to $1.3 million in 2024, then grew by 18.46% to $1.5 million in 2025, then decreased by 1.76% to $1.5 million in 2026.
- Business Quant data shows LCTX's Operating Leases at $1.5 million in Q1 2026, $1.5 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.33 Mn |
| Mar 31, 2026 | 1.51 Mn |
| Dec 31, 2025 | 1.53 Mn |
| Sep 30, 2025 | 1.52 Mn |
| Jun 30, 2025 | 1.06 Mn |
| Mar 31, 2025 | 1.01 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 1.53 Mn |
| Jun 30, 2024 | 1.77 Mn |
| Mar 31, 2024 | 2.07 Mn |
| Dec 31, 2023 | 1.98 Mn |
| Sep 30, 2023 | 2.05 Mn |
| Jun 30, 2023 | 2.30 Mn |
| Mar 31, 2023 | 2.54 Mn |
| Dec 31, 2022 | 2.86 Mn |
| Sep 30, 2022 | 2.22 Mn |
| Jun 30, 2022 | 1.46 Mn |
| Mar 31, 2022 | 1.78 Mn |
| Dec 31, 2021 | 1.94 Mn |
| Sep 30, 2021 | 1.89 Mn |